Author:
Azie Nkechi E.,Adams Gregory,Darpo Borje,Francom Steven F.,Polasek Emery C.,Wisser Joy M.,Fleishaker Joseph C.
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine,General Medicine
Reference30 articles.
1. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes
2. The significance of QT interval in drug development
3. 3. Food and Drug Administration and Health Canada . The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs . Preliminary Concept paper, 2002 . Available athttp//www.fda.gov/cder/workshop.htm#upcoming.
4. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology
5. 5. Committee for Proprietary Medicinal Products (CPMP/986/96). EMEA. Points to Consider: The assessment of the Potential for QT Interval Prolongation by Non-cardiovascular Medicinal Products ., 1997 , London.
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献